Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Trillium Therapeutic (TRIL)

Trillium Therapeutic (TRIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,311
  • Shares Outstanding, K 28,038
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,290 K
  • 60-Month Beta 2.89
  • Price/Sales 971.62
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.24
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +47.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.83 +442.17%
on 12/30/19
4.86 -7.41%
on 01/24/20
+3.59 (+394.51%)
since 12/27/19
3-Month
0.24 +1,771.10%
on 10/31/19
4.86 -7.41%
on 01/24/20
+4.23 (+1,570.38%)
since 10/25/19
52-Week
0.24 +1,771.10%
on 10/31/19
4.86 -7.41%
on 01/24/20
+2.74 (+155.68%)
since 01/25/19

Most Recent Stories

More News
Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it...

TRIL : 4.28 (-5.10%)
Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it...

TRIL : 4.28 (-5.10%)
Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the...

TRIL : 4.28 (-5.10%)
Biotechnological Breakthroughs Help Revamp the Fight Against Cancer

Biotechnology plays an important role throughout various sectors by improving industry standards, services, and developing new products. While agriculture, material science and environmental science are...

TOMDF : 0.0350 (unch)
AGEN : 3.71 (-1.85%)
LPTX : 1.86 (-2.11%)
TRIL : 4.28 (-5.10%)
VSTM : 1.77 (-5.35%)
Thinking about buying stock in Cronos Group, Delta Air Lines, Lennar Corp, Constellation Brands, or Trillium Therapeutics?

InvestorsObserver issues critical PriceWatch Alerts for CRON, DAL, LEN, STZ, and TRIL.

STZ : 190.48 (-0.56%)
DAL : 56.16 (-4.51%)
LEN : 66.44 (-0.30%)
TRIL : 4.28 (-5.10%)
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update...

TRIL : 4.28 (-5.10%)
Is the Options Market Predicting a Spike in Trillium (TRIL) Stock?

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

TRIL : 4.28 (-5.10%)
Pharmaceuticals Step Up Their Efforts to Combat the Spread of Cancer

The cancer treatment industry has grown to be one of the largest marketplaces in the world due to the disease's global prevalence. The Centers for Disease Control and Prevention (CDC) estimated that between...

ONPH : 0.0155 (-22.50%)
LPTX : 1.86 (-2.11%)
DMPI : 0.54 (unch)
TRIL : 4.28 (-5.10%)
TOCA : 0.55 (-1.79%)
Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial...

TRIL : 4.28 (-5.10%)
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.

JNJ : 147.87 (-0.30%)
TRIL : 4.28 (-5.10%)
PTLA : 13.34 (-2.27%)
PCRX : 43.69 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade TRIL with:

Business Summary

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin...

See More

Key Turning Points

2nd Resistance Point 5.38
1st Resistance Point 4.94
Last Price 4.28
1st Support Level 3.99
2nd Support Level 3.48

See More

52-Week High 4.86
Last Price 4.28
Fibonacci 61.8% 3.10
Fibonacci 50% 2.55
Fibonacci 38.2% 2.01
52-Week Low 0.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar